General Information of Drug (ID: DM2F4GT)

Drug Name
L-694247 Drug Info
Synonyms
137403-12-4; L-694,247; N-(4-((5-(3-(2-Aminoethyl)-1H-indol-5-yl)-1,2,4-oxadiazol-3-yl)methyl)phenyl)methanesulfonamide; L-694247; L 694247; 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine; N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide; Methanesulfonamide,N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]-; Tocris-0781; Biomol-NT_000112; GTPL15; AC1L30BK
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Terminated [1]
Cross-matching ID
PubChem CID
132059
ChEBI ID
CHEBI:92341
CAS Number
CAS 137403-12-4
TTD Drug ID
DM2F4GT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [3]
Eletriptan DMW649X Migraine 8A80 Approved [4]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [4]
Frovatriptan DM7RE8P Migraine 8A80 Approved [4]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [5]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [6]
Almogran DM7I64Z Migraine 8A80 Approved [7]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [8]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [9]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 15).
2 L-694,247: a potent 5-HT1D receptor agonist. Br J Pharmacol. 1993 Nov;110(3):1196-200.
3 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
6 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
7 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
8 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Company report (NeurAxon)